Stories from news aggregators
- Breaking: Helus’ Deuterated Psilocin Hits Primary Endpoint in First Phase 3
- Podcast: Compass Files Psilocybin Application with FDA, U.S. Government Taps Mark Cuban to Develop Ibogaine, Psychedelics After the Midterms
- Field Notes #6: Dispatches from D.C. as Three Psychedelics Land at FDA
- Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network
- 220 Patients or 20,000? Clinics Split on Psychedelics’ First Year
- Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA
- Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date
- Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona
- Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine
- Usona Files Psilocybin for Depression NDA as Race With Compass Tightens
- FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending
- Pharma Moves In: Investors, Developers and Lilly’s Carole Ho at the Psychedelic Healthcare Forum
- Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket
- Before the Approvals Arrive: Norway, Germany, Switzerland, the UK and Estonia at TAIP Conference 2026
- Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In on Psychedelic Access
Articles from psychedelic websites/publications
- Breaking: Helus’ Deuterated Psilocin Hits Primary Endpoint in First Phase 3
- Podcast: Compass Files Psilocybin Application with FDA, U.S. Government Taps Mark Cuban to Develop Ibogaine, Psychedelics After the Midterms
- Field Notes #6: Dispatches from D.C. as Three Psychedelics Land at FDA
- Breaking: U.S. Government Taps Mark Cuban’s Company to Develop Ibogaine for PTSD; Commits to Fund $20M Real-World Evidence Network
- 220 Patients or 20,000? Clinics Split on Psychedelics’ First Year
- Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA
- Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date
- Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona
- Podcast: Usona Files Psilocybin Application, We Review 610 Comments Submitted to FDA, and FDA Approves NRx’s Generic Ketamine
- Usona Files Psilocybin for Depression NDA as Race With Compass Tightens
- FDA Approves NRx’s Preservative-Free Generic Ketamine, but Its Bid to Ban Rivals’ Products Remains Pending
- Pharma Moves In: Investors, Developers and Lilly’s Carole Ho at the Psychedelic Healthcare Forum
- Mostly Supportive, Somewhat Divided: Stakeholders Respond to FDA’s Psychedelics Docket
- Before the Approvals Arrive: Norway, Germany, Switzerland, the UK and Estonia at TAIP Conference 2026
- Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In on Psychedelic Access
